Small Molecules—Prospective Novel HCMV Inhibitors
Human cytomegalovirus (HCMV), a member of the betaherpesvirinae, can cause life-threatening diseases. HCMV is globally widespread, with a seroprevalence in adults varying from 50 to 100%. HCMV infection is rarely of significant consequence in immunocompetent individuals. However, although immune con...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/3/474 |
| _version_ | 1797541549130645504 |
|---|---|
| author | Elke Bogner Anna Egorova Vadim Makarov |
| author_facet | Elke Bogner Anna Egorova Vadim Makarov |
| author_sort | Elke Bogner |
| collection | DOAJ |
| description | Human cytomegalovirus (HCMV), a member of the betaherpesvirinae, can cause life-threatening diseases. HCMV is globally widespread, with a seroprevalence in adults varying from 50 to 100%. HCMV infection is rarely of significant consequence in immunocompetent individuals. However, although immune control is efficient, it cannot achieve the clearance of the virus. HCMV persists lifelong in the infected host and reactivates in certain circumstances. In neonates and in immunocompromised adults, HCMV is a serious pathogen that can cause fatal organ damage. Different antiviral compounds alone or in combination have been used for the treatment of HCMV diseases. In clinical use, mutations in the viral DNA polymerase or the terminase confer resistance to ganciclovir, foscarnet, cidofovir, and letermovir. There is an urgent need to find new well-tolerated compounds supporting different modes of action. The list of novel small molecules that might have anti-HCMV activity has grown in recent years. In this short review, a selection of compounds in clinical trials and novel inhibitors targeting host-cell factors or viral proteins is presented, and their modes of action, described. |
| first_indexed | 2024-03-10T13:17:31Z |
| format | Article |
| id | doaj.art-90f568ec2a2545098f1c258a774537e8 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T13:17:31Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-90f568ec2a2545098f1c258a774537e82023-11-21T10:17:43ZengMDPI AGViruses1999-49152021-03-0113347410.3390/v13030474Small Molecules—Prospective Novel HCMV InhibitorsElke Bogner0Anna Egorova1Vadim Makarov2Institute of Virology, Charité—Universitätsmedizin Berlin, 10117 Berlin, GermanyResearch Center of Biotechnology RAS, 119071 Moscow, RussiaResearch Center of Biotechnology RAS, 119071 Moscow, RussiaHuman cytomegalovirus (HCMV), a member of the betaherpesvirinae, can cause life-threatening diseases. HCMV is globally widespread, with a seroprevalence in adults varying from 50 to 100%. HCMV infection is rarely of significant consequence in immunocompetent individuals. However, although immune control is efficient, it cannot achieve the clearance of the virus. HCMV persists lifelong in the infected host and reactivates in certain circumstances. In neonates and in immunocompromised adults, HCMV is a serious pathogen that can cause fatal organ damage. Different antiviral compounds alone or in combination have been used for the treatment of HCMV diseases. In clinical use, mutations in the viral DNA polymerase or the terminase confer resistance to ganciclovir, foscarnet, cidofovir, and letermovir. There is an urgent need to find new well-tolerated compounds supporting different modes of action. The list of novel small molecules that might have anti-HCMV activity has grown in recent years. In this short review, a selection of compounds in clinical trials and novel inhibitors targeting host-cell factors or viral proteins is presented, and their modes of action, described.https://www.mdpi.com/1999-4915/13/3/474human cytomegalovirusantiviral therapysmall molecules |
| spellingShingle | Elke Bogner Anna Egorova Vadim Makarov Small Molecules—Prospective Novel HCMV Inhibitors Viruses human cytomegalovirus antiviral therapy small molecules |
| title | Small Molecules—Prospective Novel HCMV Inhibitors |
| title_full | Small Molecules—Prospective Novel HCMV Inhibitors |
| title_fullStr | Small Molecules—Prospective Novel HCMV Inhibitors |
| title_full_unstemmed | Small Molecules—Prospective Novel HCMV Inhibitors |
| title_short | Small Molecules—Prospective Novel HCMV Inhibitors |
| title_sort | small molecules prospective novel hcmv inhibitors |
| topic | human cytomegalovirus antiviral therapy small molecules |
| url | https://www.mdpi.com/1999-4915/13/3/474 |
| work_keys_str_mv | AT elkebogner smallmoleculesprospectivenovelhcmvinhibitors AT annaegorova smallmoleculesprospectivenovelhcmvinhibitors AT vadimmakarov smallmoleculesprospectivenovelhcmvinhibitors |